Immunovant, Inc. (IMVT) Financials
IMVT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 711.4 million | 32.1 million |
2023-09-30 | 292.1 million | 40.3 million |
2023-06-30 | 351.2 million | 51.4 million |
2023-03-31 | 405.8 million | 43.3 million |
IMVT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -47.2 million | 10.2 million |
2023-09-30 | -60.1 million | 10.5 million |
2023-06-30 | -47.4 million | 10.7 million |
2023-03-31 | -55.8 million | 7.5 million |
IMVT Net Income
No data available :(
IMVT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 690.9 million | - | 306000 |
2023-09-30 | 269.9 million | - | 614000 |
2023-06-30 | 330.0 million | - | 919000 |
2023-03-31 | 376.5 million | - | 1.2 million |
IMVT Shares Outstanding
IMVT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 131000 | 48.3 million | 13.2 million | - |
2023-09-30 | 34000 | 48.0 million | 13.8 million | - |
2023-06-30 | 45000 | 50.6 million | 15.4 million | - |
2023-03-31 | 26000 | 51.8 million | 12.4 million | - |
IMVT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 58000 |
2023-09-30 | - | 349000 |
2023-06-30 | - | 343000 |
2023-03-31 | - | 341000 |
IMVT
Price: $29.06
52 week price:
Earnings Per Share: -1.81 USD
P/E Ratio: -17.82
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 791496
Market Capitalization: 4.2 billion